+15.6%
TMUS vs GSK
+63.2%
-47.6%
-44.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.9% | -0.2% | +1.0% | +0.9% |
| 7D | +3.6% | +1.7% | +1.9% | +3.3% |
| 30D | -3.4% | +7.0% | -10.4% | -4.2% |
| 3M | -9.5% | -2.7% | -6.8% | -9.3% |
| 6M | -15.2% | +1.4% | -16.6% | -15.4% |
| YTD | -18.9% | +5.3% | -24.3% | -20.0% |
| 1Y | -17.7% | +10.6% | -28.3% | -19.3% |
| 3Y | +15.6% | +62.6% | -46.9% | +8.7% |
| All | +15.6% | +63.2% | -47.6% | +8.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling